Drug intelligence / Profile preview

TYG100

Development stage: Discontinued
Lead developer: TYG Oncology
Modality: Vaccines & Immunotherapeutics

Overview

TYG100 is an active checkpoint control immunotherapy (ACCI) vaccine developed for the treatment of pancreatic and other gastrointestinal cancers. It is based on OncoQR’s modular S-TIR™ technology platform, which enhances immunogenicity by coupling a validated gastrin antigen with an improved immune-modulating carrier. The vaccine targets gastrin (G17), a peptide hormone implicated in tumor growth, and induces a rapid, strong, and clinically relevant immune response in all vaccinated individuals within two weeks after a single dose. Preclinical studies have shown that TYG100 elicits immune responses several orders of magnitude stronger than its predecessor G17DT, with no observed serious adverse events[2][4][7].

Other names: TYG-100TYG100TYG 100APL 810APL810APL-810OQR 100OQR100OQR-100

Beyond the preview

Go deeper on TYG100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TYG100.

Explore the full profile